检索结果-内蒙古大学图书馆

中国科技期刊数据库医药 2022年第1期 018-023页

作者：阮强陈皖京程云生汪泳安徽医科大学第二附属医院安徽合肥230000

筛选肥胖合并卵巢囊肿患者的诊断指标,并评估这些指标在肥胖合并卵巢囊肿患者中的筛查价值。方法:回顾性分析 2020年1月-2021年3月入住安徽医科大学第二附属医院减重代谢中心的单纯性肥胖及肥胖合并卵巢囊肿患者共 146 例,完善一般资料... 详细信息

筛选肥胖合并卵巢囊肿患者的诊断指标,并评估这些指标在肥胖合并卵巢囊肿患者中的筛查价值。方法:回顾性分析 2020年1月-2021年3月入住安徽医科大学第二附属医院减重代谢中心的单纯性肥胖及肥胖合并卵巢囊肿患者共 146 例,完善一般资料测量,并在住院当天行妇科彩超(经阴道)及腹盆腔 cT,且所有患者均于次日清晨行 TSH、c 肽、性激素六项及糖化血红蛋白等,分析肥胖合并卵巢囊肿的临床特点及影响因素。结果:共纳入146例肥胖患者,其中单纯性肥胖患者70人,肥胖合并卵巢囊肿患者76人。采用多因素Logistic回归分析显示卵巢囊肿的独立影响因素主要包括 c 肽、TSH 和腰臀比(p<0.05),受试者工作特征曲线(ROc)分析显示 c 肽、TSH 和腰臀比的曲线下面积(AUc)分别为:0.851、0.832、0.726,联合使用c肽、TSH和腰臀比可提高 AUc(0.916),在肥胖合并卵巢囊肿患者的诊断中灵敏度为 92.0%,特异度为 85.8%。结论:1.对于肥胖患者,c肽、TSH 和腰臀比联合检测具有很好的灵敏度及良好特异度,可用于肥胖合并卵巢囊肿患者的筛查;2.c 肽与TSH可能与卵巢囊肿直径的大小密切相关。

关键词：肥胖卵巢囊肿 TSH c 肽筛查

来源：评论

学校读者我要写书评

暂无评论

Fuzzy Logic Strategy for Solving an Optimal control Problem of Therapeutic Hepatitis c Virus Dynamics

引用

Open Journal of Applied Sciences 2015年第9期5卷 527-541页

作者： Jean Marie Ntaganda Mahamat Saleh Daoussa Haggar Benjamin Mampassi College of Science and Technology School of Sciences Department of Mathematics University of Rwanda Butare Rwanda Department of Mathematics Faculty of Exact and Applied Sciences N’Djamena University N’Djamena Chad Department of Mathematics Faculty of Sciences and Technology Dakar University Dakar Senegal

This paper aims at the development of an approach integrating the fuzzy logic strategy for a therapeutic hepatitis c virus dynamics optimal control problem. To test the efficiency of this strategy, the authors propose a numerical comparison with the direct method by taking the values of determinant parameters of this disease for people administrating the drugs. The results are in good agreement with experimental data.

关键词： Fuzzy Logic Optimal control Membership Function Membership Degree Hepatitis c Virus Uninfected Hepatocytes Infected Hepatocytes Numerical Simulation

来源：评论

学校读者我要写书评

暂无评论

Natural interferon-beta treatment for patients with chronic hepatitis c in Japan

引用

World Journal of Hepatology 2015年第8期7卷 1125-1132页

作者： Reina Sasaki Tatsuo Kanda Shingo Nakamoto Yuki Haga Masato Nakamura Shin Yasui Xia Jiang Shuang Wu Makoto Arai Osamu Yokosuka Department of Gastroenterology and Nephrology Chiba University Graduate School of Medicine

chronic hepatitis c virus(HcV) infection can cause liver cirrhosis and hepatocellular carcinoma(Hcc). Several studies have demonstrated that the eradication of HcV reduces the occurrence of Hcc. In Japan, as many people live to an advanced age, HcV-infected patients are also getting older, and the age at Hcc diagnosis has also increased. Although older HcV-infected patients have a risk of developing Hcc, the treatment response to peginterferon-alpha plus ribavirin therapy is relatively poor in these patients because of drop-out or discontinuation of this treatment due to adverse events. It is established that the mechanism of action between interferon-alpha and interferon-beta is slightly different. Short-term natural interferon-beta monotherapy is effective for patients with acute hepatitis c and patients infected with HcV genotype 2 and low viral loads. Natural interferon-beta plus ribavirin for 48 wk or for 24 wk are also effective for some patients with HcV genotype 1 or HcV genotype 2. Natural interferon-beta plus ribavirin has been used for certain "difficult-totreat" HcV-infected patients. In the era of direct-acting anti-virals, natural interferon-beta plus ribavirin may be one of the therapeutic options for special groups of HcV-infected patients. In the near future, signal transduction pathways of interferon-beta will inform further directions.

关键词： Hepatocellular carcinoma Hepatitis c virus Interferon-beta Interferon resistance Ribavirin

来源：评论

学校读者我要写书评

暂无评论

Sensitive determination of uric acid by using graphene quantum dots as a new substrate for immobilisation of uric oxidase

Sensitive determination of uric acid by using graphene quant...

引用

1st International conference on Nanoscience and Nanotechnology (IcNAN)

作者： Yu, Hong-Wei Zhang, Ze Shen, Tao Jiang, Jing-Hui chang, Dong Pan, Hong-Zhi Fudan Univ Shanghai Pudong Hosp Dept Clin Lab Pudong Med Ctr 2800 Gongwei Rd Shanghai 201399 Peoples R China Fudan Univ Shanghai Pudong Hosp Dept Outpatient Dept Pudong Med Ctr 2800 Gongwei Rd Shanghai 201399 Peoples R China Harbin Med Univ Affiliated Hosp 1 23 Youzheng St Harbin 150001 Heilongjiang Peoples R China Shanghai Univ Med & Hlth Sci 279 Zhouzhu Rd Shanghai 201318 Peoples R China

A novel strategy for highly sensitive electrochemical detection of uric acid (UA) was proposed based on graphene quantum dots (GQDs), GQDs were introduced as a suitable substrate for enzyme immobilisation. Uric oxidase (UOx) was immobilised on GQDs modified glassy carbon electrode (GcE). Transmission electron microscope, scanning electron microscopy, cyclic voltammetry and electrochemical impedance spectroscopy techniques were used for characterising the electrochemical biosensor. The developed biosensor responds efficiently to UA presence over the concentration linear range 1-800M with the detection limit 0.3M. This novel biosensing platform based on UOx/GQDs electrode responded even more sensitively than that based on GcE modified by UOx alone. The inexpensive, reliable and sensitive sensing platform based on UOx/GQDs electrode provides wide potential applications in clinical.

关键词： organic compounds graphene devices quantum dots enzymes biosensors biochemistry electrochemical electrodes electrochemical sensors transmission electron microscopy scanning electron microscopy voltammetry (chemical analysis) electrochemical impedance spectroscopy nanomedicine molecular biophysics sensitive uric acid determination graphene quantum dots uric oxidase immobilisation electrochemical detection GQD enzyme immobilisation glassy carbon electrode GcE transmission electron microscope scanning electron microscopy cyclic voltammetry electrochemical impedance spectroscopy electrochemical biosensor c

来源：评论

学校读者我要写书评

暂无评论

Pharmaceutical management of hepatitis B and c in liver and kidney transplant recipients

引用

World Journal of Gastrointestinal Pharmacology and Therapeutics 2015年第4期6卷 105-110页

作者： chrysoula Pipili Evangelos cholongitas Division of Nephrology Royal Infirmary of Edinburgh 4th Department of Internal Medicine Medical School of Aristotle University Hippokration General Hospital of Thessaloniki

The combination of hepatitis B immune globulin with entecavir or tenofovir(at least for a certain period of time) seems to be the most reasonable prophylaxis against recurrent hepatitis B after liver transplantation. Entecavir represents an attractive option for treatment of na?ve kidney transplant recipients, because of its high efficacy and the low rates of resistance. However antiviral treatment should be individualized in the view of kidney function and the previous resistance. To date, new captivating therapeutic strategies could make interferon-free regimens viable for treatment of hepatitis c virus positive liver transplant recipients. The recent combinations of sofosbuvir with simeprevir or daclatasvir or ledipasvir plus/minus ribavirin have boosted the on treatment and sustained virological response to rates approaching 100% within liver transplant recipients with recurrent chronic hepatitis c(cHc). Preliminary data showed that the second generation direct oral antivirals could result to high treatment rates of recurrent cHc in kidney transplant recipients as well. Ongoing studies will clarify the optimal treatment of recurrent cHc in kidney transplant recipients.

关键词： Viral hepatitis Hepatitis c recurrence Hepatitis B

来源：评论

学校读者我要写书评

暂无评论

Antiviral therapies for chronic hepatitis c virus infection with cirrhosis

引用

World Journal of Hepatology 2015年第8期7卷 1133-1141页

作者： Shingo Nakamoto Tatsuo Kanda Hiroshi Shirasawa Osamu Yokosuka Depart-ment of Gastroenterology and Nephrology Chiba UniversityGraduate School of Medicine Department of Molecular Virology Chiba University Graduate School of Medicine

Patients who are infected with hepatitis c virus(HcV) and also have advanced fibrosis or cirrhosis have beenrecognized as "difficult-to-treat" patients during an era when peginterferon and ribavirin combination therapy is the standard of care. Recent guidelines have clearly stated that treatment should be prioritized in this population to prevent complications such as decompensation and hepatocellular carcinoma. Recent advances in the treatment of chronic hepatitis c have been achieved through the development of direct-acting antiviral agents(DAAs). Boceprevir and telaprevir are first-generation DAAs that inhibit the HcV NS3/4A protease. Boceprevir or telaprevir, in combination with peginterferon and ribavirin, improved the sustained virological response rates compared with peginterferon and ribavirin alone and were tolerated in patients with HcV genotype 1 infection without cirrhosis or compensated cirrhosis. However, the efficacy is lower especially in prior non-responders with or without cirrhosis. Furthermore, a high incidence of adverse events was observed in patients with advanced liver disease, including cirrhosis, in real-life settings. current guidelines in the United States and in some European countries no longer recommend these regimens for the treatment of HcV. Next-generation DAAs include second-generation HcV NS3/4A protease inhibitors, HcV NS5 A inhibitors and HcV NS5 B inhibitors, which have a high efficacy and a lower toxicity. These drugs are used in interferon-free or in interferon-based regimens with or without ribavirin in combination with different classes of DAAs. Interferon-based regimens, such as simeprevir in combination with peginterferon and ribavirin, are well tolerated and are highly effective especially in treatmentnave patients and in patients who received treatment but who relapsed. The efficacy is less pronounced in nullresponders and in patients with cirrhosis. Interferonfree regimens in combination with ribavirin and/or two or mo

关键词： Hepatitis c virus Hepatocellular carcinoma Interferon-free regimen Liver cirrhosis Direct-actingantiviral agent

来源：评论

学校读者我要写书评

暂无评论

Update on hepatitis B and c virus diagnosis

引用

World Journal of Virology 2015年第4期4卷 323-342页

作者： Livia Melo Villar Helena Medina cruz Jakeline Ribeiro Barbosa cristianne Sousa Bezerra Moyra Machado Portilho Letícia de Paula Scalioni Viral Hepatitis Laboratory Oswaldo Cruz Institute Oswaldo Cruz Foundation

Viral hepatitis B and c virus(HBV and HcV) are responsible for the most of chronic liver disease worldwide and are transmitted by parenteral route, sexual and vertical transmission. One important measure to reduce the burden of these infections is the diagnosis of acute and chronic cases of HBV and HcV. In order to provide an effective diagnosis and monitoring of antiviral treatment, it is important to choose sensitive, rapid, inexpensive, and robust analytical methods. Primary diagnosis of HBV and HcV infection is made by using serological tests for detecting antigens and antibodies against these viruses. In order to confirm primary diagnosis, to quantify viral load, to determine genotypes and resistance mutants for antiviral treatment, qualitative and quantitative molecular tests are used. In this manuscript, we review the current serological and molecular methods for the diagnosis of hepatitis B and c.

关键词： Diagnostic methods Genotypes Hepatitis B virus Molecular diagnostic techniques Serological tests Hepatitis c virus

来源：评论

学校读者我要写书评

暂无评论

Variables Associated with cirrhosis Diagnosis in Patients with chronic Hepatitis c: A case-control Study

引用

Health 2015年第12期7卷 1634-1641页

作者： Gilmar Amorim de Sousa Iris do céu clara costa Dyego Leandro Bezerra de Souza Fabia Barbosa de Andrade Lívia Medeiros Soares celani Ranna Santos Pessoa Marlon césar de Souza Filho Daniel Fernandes Mello de Oliveira Luana Lopes de Medeiros Lucila Samara Dantas de Oliveira Maria Flávia Monteiro The Integrated Department of Medicine Federal University of Rio Grande do Norte UFRN Natal Brazil The Post-Graduate Program in Collective Health of UFRN Natal Brazil Gastroenterology Program of the University Hospital Onofre Lopes/UFRN Natal Brazil The Medical School of UFRN Natal Brazil

The diagnosis of liver cirrhosis in patients with chronic hepatitis c has not always been easy, since the gold standard method is the liver biopsy, which is an invasive procedure with interobserver accuracy problems and there have been reports of complications including records of deaths due to hemoperitoneum. cirrhosis changes the prognosis of the subject with hepatitis c and requires a different clinical management. This study aimed to identify clinical and laboratory variables associated with the diagnosis of cirrhosis in the ultrasonography of patients infected with hepatitis c. In a case-control study, we evaluated 70 cirrhotic patients with chronic hepatitis c compared to a control group of 70 non-cirrhotic people with positive HcV. The results showed, through logistic regression analysis, that the variables blood donor and professional athlete, adjusted for alcohol consumption, showed OR 0.24 and 0.18, with p values of 0.044 and 0.035, respectively. We conclude that the diagnosis of cirrhosis in patients with chronic hepatitis c remains challenging, but the patients with the condition of blood donor or professional athlete prove to be less likely to cirrhosis in ultrasonography in the initial consultation.

关键词： cirrhosis Biomakers Fibrosis Hepatitis c Virus clinical Diagnosis Biopsy Non-Invasive Methods Scores Ultrasonography

来源：评论

学校读者我要写书评

暂无评论

SOFRITAS: Serializable Ordering-Free Regions for Increasing Thread Atomicity Scalably 18

SOFRITAS: Serializable Ordering-Free Regions for Increasing ...

引用

23rd International conference on Architectural Support for Programming Languages and Operating Systems (ASPLOS)

作者： DeLozier, christian Lucia, Brandon Eizenberg, Ariel Devietti, Joseph Univ Penn Philadelphia PA 19104 USA Carnegie Mellon Univ Pittsburgh PA 15213 USA

ISBN: (纸本)9781450349116

correctly synchronizing multithreaded programs is challenging and errors can lead to program failures such as atomicity violations. Existing strong memory consistency models rule out some possible failures, but are limited by depending on programmer-defined locking code. We present the new Ordering-Free Region (OFR) serializability consistency model that ensures atomicity for OFRs, which are spans of dynamic instructions between consecutive ordering constructs (e.g., barriers), without breaking atomicity at lock operations. Our platform, Serializable Ordering-Free Regions for Increasing Thread Atomicity Scalably (SOFRITAS), ensures a c/c++ program's execution is equivalent to a serialization of OFRs by default. We build two systems that realize the SOFRITAS idea: a concurrency bug finding tool for testing called SofriTest, and a production runtime system called SoPro. SofriTest uses OFRs to find concurrency bugs, including a multi-critical-section atomicity violation in memcached that weaker consistency models will miss. If OFRs are too coarse-grained, SofriTest suggests refinement annotations automatically. Our software-only SoPro implementation has high performance, scales well with increased parallelism, and prevents failures despite bugs in locking code. SoPro has an average overhead of just 1.59x on a single-threaded execution and 1.51x on sixteen threads, despite pthreads' much weaker memory model.

关键词： atomicity region serializability data races c c plus

来源：评论

学校读者我要写书评

暂无评论

Treatment of chronic hepatitis c in patients with HIV/HcV coinfection

引用

World Journal of Virology 2015年第1期4卷 1-12页

作者： Nicola coppola Salvatore Martini Mariantonietta Pisaturo caterina Sagnelli Pietro Filippini Evangelista Sagnelli Department of Mental Health and Public Medicine Section of Infectious DiseasesSecond University of Naples Division of Infectious Diseases AORN Sant’Anna e San Sebastiano di Caserta Department of Clinical and Experimental Medicine and Surgery "F.Magrassi e A.Lanzara" Second University of Naples

Hepatitis c virus(HcV) infection is one of the mostfrequent causes of comorbidity and mortality in the human immunodeficiency virus(HIV) population, and liver-related mortality is now the second highest cause of death in HIV-positive patients, so HcV infection should be countered with adequate antiviral therapy. In 2011 began the era of directly acting antivirals(DAAs) and the HcV NS3/4A protease inhibitors telaprevir and boceprevir were approved to treat HcV-genotype-1 infection, each one in combination with pegylated interferon alfa(Peg-IFN) + ribavirin(RBV). The addition of the first generation DAAs, strongly improved the efficacy of antiviral therapy in patients with HcVgenotype 1, both for the HcV-monoinfected and HIV/HcV coinfected, and the poor response to Peg-IFN + RBV in HcV/HIV coinfection was enhanced. These treatments showed higher rates of sustained virological response than Peg-IFN + RBV but reduced tolerability and adherence due to the high pill burden and the several pharmacokinetic interactions between HcV NS3/4A protease inhibitors and antiretroviral drugs. Then in 2013 a new wave of DAAs arrived, characterized by high efficacy, good tolerability, a low pill burden and shortened treatment duration. The second and third generation DAAs also comprised IFN-free regimens, which in small recent trials on HIV-positive patients have shown comforting preliminary results in terms of efficacy, tolerability and adherence.

关键词： Hepatitis c virus infection Human immunodeficiency virus infection Anti-hepatitis c virus treatment Directly acting antivirals HIV/HcV coinfection chronic hepatitis c

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：